PegIntron or Pegasys 2008

Back to Main Page

Research on Pegasys and PegIntron

Back to 2009

Click here for :2007-2004

Dec

Pegasys EMEA Approval for Retreatment for 72 Weeks in Nonresponders

Long-term Low-dose Pegylated Interferon May Improve Liver Inflammation and Fibrosis in a Select Subgroup of Prior Non-responders

Is Maintenance Therapy with Pegylated Interferon Monotherapy Ineffective-or Even Harmful to Patients?

AASLD: Evaluation of a 4 Week Lead-in Phase with Nitazoxanide (NTZ) prior to Peginterferon (PegIFN) plus NTZ for Treatment of Chronic Hepatitis C: Final Report -

Treatment-Related Anemia Is Associated With Higher SVR Rates Among Persons Treated With Peginterferon (PEG)/Ribavirin (RBV): Results From the IDEAL Study - (12/01/08)

A 72-week treatment duration with peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) has a favorable risk:benefit ratio in non-responders to pegylated interferon alfa-2b (12KD) plus ribavirin: findings of the multinational REPEAT study

Probability of virologic relapse during follow-up varies with the rapidity of the on-treatment virologic response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin -

Phase 2 Study of Telaprevir Administered q8h or q12h with Peginterferon Alfa-2a or Alfa-2b and Ribavirin in Treatment-naïve Patients with Genotype 1 Hepatitis C: Week 12 Interim Results -

Randomized study comparing Peginterferon alfa2a plus Ribavirin and Peginterferon alfa2b plus Ribavirin in naïve patients with chronic hepatitis C: Final results of the MiIan Safety and Tolerability (MIST) Study

SVR in African American Patients: Results of the IDEAL Study (Individualized Dosing Efficacy vs Flat Dosing to Assess OptimaL Pegylated Interferon Therapy) - (11/21/08)
 

Nov

Decreased Riba Predictor Of Relapse? 

Do growth factors improve SVR?

High-Dose Peg alfa-2b No Improved SVR rate  

Slow Responder  Geno1- Benefit Extended TX to 72wks

4wk Nonresponse Predicts Failure To SVR

HCV Protease Inhibitor Boceprevir plus Pegylated Interferon/Ribavirin Increases Sustained Virological Response Rate: SPRINT-1 Study

New Study Shows That Pegasys Regimen Provides Higher Cure Rates For Hepatitis C Patients

ZymoGenetics Reports Positive Interim Phase 1b Results In Hepatitis C

Oct-Sept

Insulin-sensitizing Agent Pioglitazone (Actos) Did Not Improve Response to Re-treatment with Pegylated Interferon plus Ribavirin

Ribavirin in the Treatment of Chronic Hepatitis C

Hep C Treatment: Comparing the Pegylated Interferons

Silymarin Improves Quality of Life During Hepatitis C Treatment

EPO Safe for Managing Anemia
 

Aug-June

Body Weight Affects Relapse Rates in Latinos with Genotype 2/3 Hepatitis C Treated with Pegylated Interferon Alfa-2a (Pegasys) plus Ribavirin

Study Demonstrates Safety of Erythropoiesis-stimulating Agents for Managing Ribavirin-related Anemia in Hepatitis C Patients

Durability of SVR

Telaprevir plus Pegylated Interferon and Ribavirin Produces Rapid Response and Is Well Tolerated in 28-day Study

Comparison of the Pegylated Interferons Pegasys and PegIntron for Treatment of Chronic Hepatitis C: Analysis of 16 Randomized Trials - 7/18/08

Pegylated Interferon Alfa-2a (Pegasys) Continues to Suppress HBV, but Adding Adefovir (Hepsera) Provides No Extra Benefit in PEG for B Trial

 EASL 2008

Sustained Virological Response to Pegylated Interferon Alfa-2b (PegIntron) with or without Ribavirin Predicts Continued Response through 5 Years

Clearance of HCV at 5-Year Follow-up for Peginterferon alfa-2b ± Ribavirin Is Predicted by Sustained Virologic Response at 24 Weeks Post-Treatment

Sustained Virologic Response and Relapse Rates With Peginterferon alfa-2b plus Ribavirin in Clinical Trials Are Comparable to Those in Community-Based Studies
 

May

Comparing Pegasys and PegIntron at EASL 2008 Milan

Randomized Controlled Trial of Nitazoxanide-Peginterferon-Ribavirin, Nitazoxanide-Peginterferon and Peginterferon-Ribavirin in the Treatment of Patients with Chronic Hepatitis C Genotype 4 -

Platelet Count Is a Strong Predictor of Sustained Response to Pegylated Interferon/ribavirin in Prior Non-Responders (EPIC 3) -

Final Results of the Phase IIIb IDEAL Study (Individualized Dosing Efficacy vs. Flat Dosing to Assess OptimaL PegInterferon Therapy) -

Peginterferon Alfa-2a (Pegasys) plus Ribavirin versus Peginterferon alfa-2b (Pegintron) Plus Ribavirin in Naive Patients with Chronic HHCV Infection: Results of a Prospective Randomized Trial -

FACTORS PREDICTIVE OF RELAPSE IN GENOTYPE 2 AND 3 PTS TREATED FOR 12 WEEKS WITH PEGIFN ALFA 2B AND WEIGHT BASED RIBAVIRIN COMBINATION

HALT-C Study Design Flawed -

April

COLCHICINE VERSUS PEG-INTERFERON ALFA 2B LONG TERM THERAPY: RESULTS OF THE 4 YEAR COPILOT TRIAL

Pegylated Interferon Maintenance Demonstrates Benefits for Hepatitis C Patients with Portal Hypertension

RIBAVIRIN CONCENTRATION AT WEEK FOUR IS AN INDEPENDEND PREDICTOR FOR SUSTAINED VIROLOGICAL RESPONSE AFTER TREATMENT OF HEPATITIS C GENOTYPE 2/3 (NORDYNAMIC TRIAL)

Factors Predicting Response to Therapy for Chronic Hepatitis C  -

Use of Different Pegylated Interferon/Ribavirin Regimens after Rapid Virological Response Does Not Affect Sustained Response Rate

Liver Gene Expression Predicts Response to Pegylated Interferon plus Ribavirin

FDA Approves Label Revisions Recommending New Robetol (ribavirin) Weight-Based Dosing Regimen: PEGINTRON PLUS WEIGHT-BASED REBETOL (ribavirin) RESULTED IN HIGHER SVR THAN FLAT DOSING; LOW RELAPSE RATES IN PATIENTS WITH CHRONIC HEPATITIS C. Schering Plough press release -

Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.

Gastroenterologists' perceptions of need and availability of psychiatric services for patients
with hepatitis C.

Quality-of-Life Tradeoffs for Hepatitis C Treatment: Do Patients and Providers Agree?

March

FDA Approves New Weight-Based Dosing Regimen for PegIntron plus Ribavirin

Use of Different Pegylated Interferon/Ribavirin Regimens after Rapid Virological Response Does Not Affect Sustained Response Rate

Pathology of Chronic Hepatitis C in Children: Peds-C Trial

Glucose >100 mg/dl Reduces Interferon/RBV SVR -

On-treatment responses at weeks 4 and 12 can be used to predict sustained virologic response rates in HIV HCV co-infected patients treated with peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS) -

Adjustment of Treatment Duration Based on Early Response

IDEAL Trial Results

Final Results of the Phase IIIb IDEAL Study (Individualized Dosing Efficacy vs. Flat Dosing to Assess OptimaL PegInterferon Therapy) - May 08

The IDEAL (Individualized Dosing Efficacy vs. Flat Dosing to Assess optimal pegylated interferon therapy)

SVR and Disease Progression

Treatment of Hepatitis C Reduces Incidence of Non-Hodgkin's Lymphoma -

-February

You must register with clinical care options to view the following slide shows

Source: New Management Strategies for HCV Nonresponders and Relapsers

Learn about the causes of nonresponse and strategies for individualizing treatment in patients with hepatitis C.

Source: Drug Resistance in Chronic Hepatitis B: From Definitions to Management Strategies

Source: CCO Independent Conference Coverage of the 2007 Annual Meeting of the American Association for the Study of Liver Diseases*